Controlled release and bioactivity of the monoclonal antibody rituximab from a porous matrix: A potential in situ therapeutic device

S. Simovic; K. R. Diener; A. Bachhuka; K. Kant; D. Losic; J. D. Hayball; M. P. Brownc; K. Vasilev

doi:10.1016/j.matlet.2014.05.110

Controlled release and bioactivity of the monoclonal antibody rituximab from a porous matrix: A potential in situ therapeutic device

S. Simovic, K. R. Diener, A. Bachhuka, K. Kant, D. Losic, J. D. Hayball, M. P. Brownc, K. Vasilev

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

We report on a platform for extended release of biologically-active therapeutic antibodies. Extended antibody release has been achieved by utilising a plasma polymer film of controlled and predetermined thickness deposited on the top of a porous platform loaded with rituximab. Antibody release kinetics directly correlates to the plasma polymer film thickness that is in turn controlled by the plasma polymer deposition time. After 1 month, 82%, 60% and 45% of the antibody is released from platforms coated with plasma polymer for 50 s, 150 s and 300 s, respectively. Activity of the released antibody was assessed in cultures of CD20-positive Daudi cells by using polyacrylamide gel electrophoresis and flow cytometry. The results from gel electrophoresis and flow cytometry indicate that the antibody had maintained its integrity during the release process. This work provides a proof-of-concept technology that achieves extended release of biologically active rituximab for more than 30 days.

Original language	English
Pages (from-to)	210-214
Number of pages	5
Journal	Materials Letters
Volume	130
DOIs	https://doi.org/10.1016/j.matlet.2014.05.110
Publication status	Published - 1 Sep 2014
Externally published	Yes

Bibliographical note

Funding Information:
KV thanks to ARC for support through fellowship FT100100292 .

Keywords

Cancer therapy
Drug release
Implant
Plasma polymerization

Access to Document

10.1016/j.matlet.2014.05.110Licence: In Copyright

Cite this

@article{e41088de22e549a98fcc19cca4937a50,

title = "Controlled release and bioactivity of the monoclonal antibody rituximab from a porous matrix: A potential in situ therapeutic device",

abstract = "We report on a platform for extended release of biologically-active therapeutic antibodies. Extended antibody release has been achieved by utilising a plasma polymer film of controlled and predetermined thickness deposited on the top of a porous platform loaded with rituximab. Antibody release kinetics directly correlates to the plasma polymer film thickness that is in turn controlled by the plasma polymer deposition time. After 1 month, 82%, 60% and 45% of the antibody is released from platforms coated with plasma polymer for 50 s, 150 s and 300 s, respectively. Activity of the released antibody was assessed in cultures of CD20-positive Daudi cells by using polyacrylamide gel electrophoresis and flow cytometry. The results from gel electrophoresis and flow cytometry indicate that the antibody had maintained its integrity during the release process. This work provides a proof-of-concept technology that achieves extended release of biologically active rituximab for more than 30 days.",

keywords = "Cancer therapy, Drug release, Implant, Plasma polymerization",

author = "S. Simovic and Diener, {K. R.} and A. Bachhuka and K. Kant and D. Losic and Hayball, {J. D.} and Brownc, {M. P.} and K. Vasilev",

note = "Funding Information: KV thanks to ARC for support through fellowship FT100100292 . ",

year = "2014",

month = sep,

day = "1",

doi = "10.1016/j.matlet.2014.05.110",

language = "English",

volume = "130",

pages = "210--214",

journal = "Materials Letters",

issn = "0167-577X",

}

TY - JOUR

T1 - Controlled release and bioactivity of the monoclonal antibody rituximab from a porous matrix

T2 - A potential in situ therapeutic device

AU - Simovic, S.

AU - Diener, K. R.

AU - Bachhuka, A.

AU - Kant, K.

AU - Losic, D.

AU - Hayball, J. D.

AU - Brownc, M. P.

AU - Vasilev, K.

N1 - Funding Information: KV thanks to ARC for support through fellowship FT100100292 .

PY - 2014/9/1

Y1 - 2014/9/1

N2 - We report on a platform for extended release of biologically-active therapeutic antibodies. Extended antibody release has been achieved by utilising a plasma polymer film of controlled and predetermined thickness deposited on the top of a porous platform loaded with rituximab. Antibody release kinetics directly correlates to the plasma polymer film thickness that is in turn controlled by the plasma polymer deposition time. After 1 month, 82%, 60% and 45% of the antibody is released from platforms coated with plasma polymer for 50 s, 150 s and 300 s, respectively. Activity of the released antibody was assessed in cultures of CD20-positive Daudi cells by using polyacrylamide gel electrophoresis and flow cytometry. The results from gel electrophoresis and flow cytometry indicate that the antibody had maintained its integrity during the release process. This work provides a proof-of-concept technology that achieves extended release of biologically active rituximab for more than 30 days.

AB - We report on a platform for extended release of biologically-active therapeutic antibodies. Extended antibody release has been achieved by utilising a plasma polymer film of controlled and predetermined thickness deposited on the top of a porous platform loaded with rituximab. Antibody release kinetics directly correlates to the plasma polymer film thickness that is in turn controlled by the plasma polymer deposition time. After 1 month, 82%, 60% and 45% of the antibody is released from platforms coated with plasma polymer for 50 s, 150 s and 300 s, respectively. Activity of the released antibody was assessed in cultures of CD20-positive Daudi cells by using polyacrylamide gel electrophoresis and flow cytometry. The results from gel electrophoresis and flow cytometry indicate that the antibody had maintained its integrity during the release process. This work provides a proof-of-concept technology that achieves extended release of biologically active rituximab for more than 30 days.

KW - Cancer therapy

KW - Drug release

KW - Implant

KW - Plasma polymerization

UR - http://www.scopus.com/inward/record.url?scp=84902148318&partnerID=8YFLogxK

U2 - 10.1016/j.matlet.2014.05.110

DO - 10.1016/j.matlet.2014.05.110

M3 - Article

AN - SCOPUS:84902148318

VL - 130

SP - 210

EP - 214

JO - Materials Letters

JF - Materials Letters

SN - 0167-577X

ER -

Controlled release and bioactivity of the monoclonal antibody rituximab from a porous matrix: A potential in situ therapeutic device

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this